Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099593 · ClinicalTrials.gov registry record · Phase 2
Immunization Against Tumor Cells in Sezary Syndrome
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00099593 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 17 participants.
The verdict
NCT00099593, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This research is being done to look at the safety and value of a vaccine for a cancer found in the blood and skin known as Cutaneous T-cell lymphoma (CTCL) and Sezary Syndrome. In the laboratory, researches found that special white blood cells, called dendritic cells (DCs), are able to stimulate the immune system (groups of cells that protect the body from germs and diseases) in a way that helps your body fight cancer. Autologous (from your own body) DCs will be prepared (mixed together) in the laboratory with your cancer cell (Sezary cells) to allow your DCs to pick up parts of your Sezary cells to make the vaccine for you.
Interventions
- BIOLOGICAL Autologous Dendritic Cell Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099593
The ClinicalTrials.gov registry entry for NCT00099593 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous Dendritic Cell Vaccine is the first listed.
NCT00099593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099593 about?
NCT00099593 is a clinical study titled "Immunization Against Tumor Cells in Sezary Syndrome". This research is being done to look at the safety and value of a vaccine for a cancer found in the blood and skin known as Cutaneous T-cell lymphoma (CTCL) and Sezary Syndrome. In the laboratory, researches found that special white blood cells, called dendritic cells (DCs), are able to stimulate th...
What is the current status of trial NCT00099593?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2004-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00099593?
The interventions under investigation include: Autologous Dendritic Cell Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00099593?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.